b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Process" Owner="NLM">\n        <PMID Version="1">31311976</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>07</Month>\n            <Day>15</Day>\n        </DateRevised>\n        <Article PubModel="Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">2045-2322</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>9</Volume>\n                    <Issue>1</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>07</Month>\n                        <Day>16</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Scientific reports</Title>\n                <ISOAbbreviation>Sci Rep</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Identifying chemopreventive agents for obesity-associated cancers using an efficient, 3D high-throughput transformation assay.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>10278</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-019-46531-y</ELocationID>\n            <Abstract>\n                <AbstractText>Obesity is associated with ~40% of cancer diagnoses but there are currently no effective preventive strategies, illustrating a need for chemoprevention. We previously demonstrated that fibroblast growth factor 2 (FGF2) from adipose tissue stimulates malignant transformation, as measured by growth in soft agar, the gold-standard in vitro transformation assay. Because the soft agar assay is unsuitable for high throughput screens (HTS), we developed a novel method using 3D growth in ultra-low attachment conditions as an alternative to growth in agar to discover compounds that inhibit transformation. Treating non-tumorigenic, skin epithelial JB6 P<sup>+</sup> cells with FGF2 stimulates growth in ultra-low attachment conditions analogous to growth in the soft agar. This transformation HTS identified picropodophyllin, an insulin growth factor 1 receptor (IGF1R) inhibitor, and fluvastatin, an HMG-CoA reductase inhibitor, as potential chemopreventive agents. These compounds were validated for efficacy using two non-tumorigenic cell lines in soft agar. Another IGF1R inhibitor and other statins were also tested and several were able to inhibit growth in soft agar. This novel 3D HTS platform is fast, robust and has the potential to identify agents for obesity-associated cancer prevention.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Benham</LastName>\n                    <ForeName>Vanessa</ForeName>\n                    <Initials>V</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI, 48824, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Bullard</LastName>\n                    <ForeName>Blair</ForeName>\n                    <Initials>B</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI, 48824, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Dexheimer</LastName>\n                    <ForeName>Thomas S</ForeName>\n                    <Initials>TS</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI, 48824, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Bernard</LastName>\n                    <ForeName>Matthew P</ForeName>\n                    <Initials>MP</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI, 48824, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Neubig</LastName>\n                    <ForeName>Richard R</ForeName>\n                    <Initials>RR</Initials>\n                    <Identifier Source="ORCID">http://orcid.org/0000-0003-0501-0008</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI, 48824, USA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Dermatology, Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, MI, 48824, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Liby</LastName>\n                    <ForeName>Karen T</ForeName>\n                    <Initials>KT</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI, 48824, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Bernard</LastName>\n                    <ForeName>Jamie J</ForeName>\n                    <Initials>JJ</Initials>\n                    <Identifier Source="ORCID">http://orcid.org/0000-0002-3800-2576</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI, 48824, USA. jbernard@msu.edu.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Dermatology, Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, MI, 48824, USA. jbernard@msu.edu.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <GrantList CompleteYN="Y">\n                <Grant>\n                    <GrantID>R00 CA177868</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>T32 ES007255</GrantID>\n                    <Acronym>ES</Acronym>\n                    <Agency>NIEHS NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n            </GrantList>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>07</Month>\n                <Day>16</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Sci Rep</MedlineTA>\n            <NlmUniqueID>101563288</NlmUniqueID>\n            <ISSNLinking>2045-2322</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2018</Year>\n                <Month>11</Month>\n                <Day>14</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>06</Month>\n                <Day>26</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>18</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>18</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>18</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>epublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31311976</ArticleId>\n            <ArticleId IdType="doi">10.1038/s41598-019-46531-y</ArticleId>\n            <ArticleId IdType="pii">10.1038/s41598-019-46531-y</ArticleId>\n            <ArticleId IdType="pmc">PMC6635484</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'